LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL
Clinical trials for LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL explained in plain language.
Never miss a new study
Get alerted when new LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL trials appear
Sign up with your email to follow new studies for LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Tailored CLL treatment aims to reduce side effects by skipping unnecessary drugs
Disease control OngoingThis study is testing a new, personalized approach for adults with untreated CLL. The goal is to see if starting with just two oral drugs is effective, and only adding a third drug (an infusion) for patients who still have detectable cancer after the first phase of treatment. Thi…
Matched conditions: LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL
Phase: PHASE2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Apr 01, 2026 18:41 UTC
-
New pill targets tough blood cancers after standard treatments fail
Disease control OngoingThis early-stage study is testing the safety and initial effectiveness of a new oral drug called LOXO-338 for patients with advanced blood cancers like leukemia and lymphoma who have already received standard therapies. The trial has two parts: first testing LOXO-338 alone, and t…
Matched conditions: LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New drug combo trial aims to control blood cancer longer
Disease control OngoingThis study is comparing two different treatment approaches for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not received prior treatment. It tests whether a combination of two newer targeted drugs (ibrutinib and venetoclax) works bet…
Matched conditions: LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Experimental T-Cell therapy enters human testing for Tough-to-Treat blood cancers
Disease control OngoingThis is the first human study of an experimental drug called JNJ-80948543, designed to redirect a patient's own immune T-cells to attack cancer cells. It is enrolling 167 adults with advanced non-Hodgkin lymphoma or chronic lymphocytic leukemia that has come back or stopped respo…
Matched conditions: LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC
-
Cancer drug safety watch: tracking Long-Term effects
Knowledge-focused ENROLLING_BY_INVITATIONThis study tracks the long-term safety of experimental cancer treatments in patients who previously participated in earlier Janssen trials. It follows 80 people with various cancers to monitor for serious side effects over time. The goal is to better understand the safety profile…
Matched conditions: LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Knowledge-focused
Last updated Mar 11, 2026 14:54 UTC